戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  pathway, is avirulent in the mouse model of systemic candidiasis.
2 r of immune defense against both mucosal and systemic candidiasis.
3 like pathogen and can cause life-threatening systemic candidiasis.
4 gal control that influences host survival in systemic candidiasis.
5 1-M280 was associated with increased risk of systemic candidiasis.
6 e (PE), and is avirulent in a mouse model of systemic candidiasis.
7 n and promotes virulence in a mouse model of systemic candidiasis.
8 es remain the "gold standard" for diagnosing systemic candidiasis.
9 , and it was avirulent in the mouse model of systemic candidiasis.
10 attenuated for virulence in a mouse model of systemic candidiasis.
11 have a protective role in host resistance to systemic candidiasis.
12 eractions was evaluated in a murine model of systemic candidiasis.
13 cans, using immunocompetent murine models of systemic candidiasis.
14 mmune cells, are particularly susceptible to systemic candidiasis.
15 nistic pathogen that causes mucosal and deep systemic candidiasis.
16 s of CAP1 were avirulent in a mouse model of systemic candidiasis.
17 e mouse model of hematogenously disseminated systemic candidiasis.
18 ponsible for about 15 percent of mucosal and systemic candidiasis.
19  resistance to gastric, anorectal, and acute systemic candidiasis.
20  to establish infection in a murine model of systemic candidiasis.
21 allenge contribute to protective immunity to systemic candidiasis.
22 nd euthymic bg/bg-nu/+ mice from mucosal and systemic candidiasis.
23 whole cell vaccine by using murine models of systemic candidiasis.
24 ation and phagocytosis and protect mice from systemic candidiasis.
25 tial drug target for new antifungals against systemic candidiasis.
26  neutropenia-related bacterial pneumonia and systemic candidiasis.
27 creases susceptibility of mice and humans to systemic candidiasis.
28 gus Candida albicans is the leading cause of systemic candidiasis, a disease with poor prognosis affe
29     Candida albicans is the leading cause of systemic candidiasis, a fungal disease associated with h
30 ht represent an accurate and early marker of systemic candidiasis, a hypothesis that should be tested
31         Candida albicans is a major cause of systemic candidiasis, a severe fungal infection with a ~
32                                              Systemic candidiasis affects 1.6 to 4.5% of very low bir
33 role of this cytokine in the pathogenesis of systemic candidiasis are not well understood.
34 48 is important for protection in a model of systemic candidiasis as shown in CD48(-/-) mice and it b
35 d female cancer patients at risk but without systemic candidiasis, bacterial communities in high Cand
36 y to secrete IL-17 are highly susceptible to systemic candidiasis, but we found that temporary blocka
37 hat hyphae are essential for pathogenesis of systemic candidiasis by C. albicans.
38 arance and host survival in a mouse model of systemic candidiasis by stimulating phagocyte effector f
39           Overall, our results indicate that systemic candidiasis can develop in the absence of HR, b
40 pha plays a key role in host defense against systemic candidiasis caused by either C. glabrata or C.
41 he hyperresistance of IL-10 KO mice to acute systemic candidiasis did not seem to correlate with nitr
42 ida albicans antigens among 60 patients with systemic candidiasis due to various Candida spp. and 24
43 ct is considered a major portal of entry for systemic candidiasis, experiments were designed to clari
44 ffect on the early, innate response to acute systemic candidiasis; however, in comparison to immunoco
45  part of the normal flora but it also causes systemic candidiasis if it reaches the bloodstream.
46     Using the simplified model, we predicted systemic candidiasis in a separate test sample of 32 pat
47 f neonatal candidiasis (NC) is distinct from systemic candidiasis in adults and older pediatric patie
48 f URA3 contributed to the severity of murine systemic candidiasis in BALB/c mice.
49                             The incidence of systemic candidiasis in bg/bg-nu/nu mice was significant
50               Previous evaluation of HWP1 in systemic candidiasis in CBA/J mice was done with Candida
51                                    Moreover, systemic candidiasis in genetic (Deltadbl/GATA) or anti-
52                     Antifungal prevention of systemic candidiasis in immunocompetent critically ill a
53 al cells and had a reduced capacity to cause systemic candidiasis in mice.
54            First, we tested the induction of systemic candidiasis in partridge and embryonated partri
55                                During murine systemic candidiasis, interruption of CCR2-dependent inf
56 were orally immunized mice more resistant to systemic candidiasis (intravenous challenge) than were g
57                                              Systemic candidiasis is a common, high-mortality, nosoco
58                                              Systemic candidiasis is a major cause of complicating in
59 an antimannan antibody in host resistance to systemic candidiasis is influenced by its IgG subclass.
60           Therefore, the role of farnesol in systemic candidiasis is likely due to its ability to inh
61                   Furthermore, in a model of systemic candidiasis, mice lacking group V sPLA(2) had a
62                                           In systemic candidiasis, microbial capture via the phagocyt
63                            In a murine acute systemic candidiasis model, C albicans strongly stimulat
64 yphal formation and decreases virulence in a systemic candidiasis model, suggesting a role for post-t
65 l of mice, decreased severity of mucosal and systemic candidiasis, modulation of immune responses, de
66 he beta2m-/- mutant mice were susceptible to systemic candidiasis of endogenous origin despite the in
67                                 No deaths or systemic candidiasis of endogenous origin were evident i
68  role of phagocytic cells during mucosal and systemic candidiasis of endogenous origin.
69 or 4 weeks showed any histologic evidence of systemic candidiasis of endogenous origin.
70  their natural susceptibility to mucosal and systemic candidiasis of endogenous origin.
71 cient to protect J(H)D mice from mucosal and systemic candidiasis of endogenous origin; however, func
72 glabrata is one of the most common causes of systemic candidiasis, often resistant to antifungal medi
73 s variant extended the survival of mice with systemic candidiasis (P < 0.001).
74               Studies using animal models of systemic candidiasis pointed to possible differences in
75  antigenic peptide, can also protect against systemic candidiasis, reducing kidney fungal load and in
76 The crude mortality rate among neonates with systemic candidiasis remains approximately 30%.
77 andidiasis of endogenous origin and to acute systemic candidiasis (resulting from intravenous injecti
78 In vivo efficacy studies in a mouse model of systemic candidiasis showed that AM2 (5) successfully cu
79 rom the kidney of antibody-treated mice with systemic candidiasis showed uniform binding of each vari
80 e resistant to oropharyngeal candidiasis and systemic candidiasis, similar to immunocompetent wild-ty
81 ere significantly higher among patients with systemic candidiasis than among controls, whereas IgM re
82  IL-4 cytokine gene were more susceptible to systemic candidiasis than were immunocompetent controls.
83 a coli cells both ex vivo and in vivo During systemic candidiasis, the absence of alphaXbeta2 resulte
84 ed to a new experimental infection model for systemic candidiasis using partridge and embryonated par
85                 Here, using a mouse model of systemic candidiasis, we found that resident macrophages
86                               In contrast to systemic candidiasis, we observed no significant (P < 0.
87 ge IL-12, are critical to resistance against systemic candidiasis, while Th2 cytokines such as IL-4 a
88 ediction model that identified patients with systemic candidiasis with an error rate of 3.7%, a sensi
89 ction with a well-established mouse model of systemic candidiasis with C. albicans A72 administered b